{"name":"Krystal Biotech, Inc.","slug":"krystal","ticker":"KRYS","exchange":"NASDAQ","domain":"krystalbio.com","description":"Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotec","hq":"Pittsburgh, PA","founded":0,"employees":"295","ceo":"Krish Krishnan","sector":"Biotech — Gene Therapy","stockPrice":267.73,"stockChange":3.74,"stockChangePercent":1.42,"marketCap":"$7.9B","metrics":{"revenue":389130000,"revenueGrowth":17.5,"grossMargin":94.1,"rdSpend":58045000,"netIncome":204831000,"cash":496304000,"dividendYield":0,"peRatio":39.1,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2033-06-01","label":"KB103 patent cliff ($0.0B at risk)","drug":"KB103","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"KB105","genericName":"KB105","slug":"kb105","indication":"Other","status":"phase_2"},{"name":"Topical Beremagene Geperpavec","genericName":"Topical Beremagene Geperpavec","slug":"topical-beremagene-geperpavec","indication":"Dystrophic epidermolysis bullosa","status":"phase_3"},{"name":"KB301","genericName":"KB301","slug":"kb301","indication":"Other","status":"phase_1"},{"name":"KB803","genericName":"KB803","slug":"kb803","indication":"Recessive dystrophic epidermolysis bullosa (RDEB)","status":"phase_3"}]}],"pipeline":[{"name":"KB105","genericName":"KB105","slug":"kb105","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Topical Beremagene Geperpavec","genericName":"Topical Beremagene Geperpavec","slug":"topical-beremagene-geperpavec","phase":"phase_3","mechanism":"Beremagene geperpavec is a gene therapy that uses a viral vector to deliver a gene to the skin, which then produces a protein to treat the condition.","indications":["Dystrophic epidermolysis bullosa"],"catalyst":""},{"name":"KB301","genericName":"KB301","slug":"kb301","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"KB803","genericName":"KB803","slug":"kb803","phase":"phase_3","mechanism":"KB803 is a gene therapy that delivers a functional COL7A1 gene to restore type VII collagen production in patients with recessive dystrophic epidermolysis bullosa.","indications":["Recessive dystrophic epidermolysis bullosa (RDEB)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Krystal Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for KB407","summary":"Krystal Biotech announced that the FDA has cleared the IND application for KB407, a gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).","drugName":"KB407","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Krystal Biotech Reports Third Quarter 2023 Financial Results","summary":"Krystal Biotech reported its third quarter 2023 financial results, with a net loss of $13.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Krystal Biotech Enters into Licensing Agreement with Pfizer for KB103","summary":"Krystal Biotech announced that it has entered into a licensing agreement with Pfizer for its lead product, KB103.","drugName":"KB103","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPV3l5TnVDNWhGTm5jUWd6WkE4cVBVWlR2X0tady10YThOUm5rcVVHX1N2dXo3SE54SzZiWUFIYnZtN1VwTVAxRkJwa0xyWUtMVGl6RDZXMjc5dFFsZ0NMZHNvSHNlSEZFUG5jTFNrWURkZXNrSnZGcjV4SFAzRzdrN0xXODVvYURSNzJhZGpvQm5mSTI2MU5hV2o1azh2T0JrYTdQalRn0gGuAUFVX3lxTE12WjIyTm9hT3J0WWFYN1NFTEdLcGVMQ3lqUjB3MVM2MFplMjZxWHhwblNKZHBsXzVNb2dWOUhzdE9xQ0phTUFjY1kwSUdhQXBNZGlFc296QllCRE5zbklLVkZOYVZNSDNpNVFxaHpSU0VXd2J6QU53aHZ4bmdMY29NeDBRZmVYWUttVDJRN3BIUXRtbEhwcFF6RGZQcmYtb0hNVE5KUVlPVkQ1aWFaQQ?oc=5","date":"2026-02-28","type":"pipeline","source":"Insider Monkey","summary":"Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224 - Insider Monkey","headline":"Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNZng1WlVHNlJXZWJHZnlKUXM0VE52LXJoVFQ1Z3hXWGhxWXNUYmNLeW1rTmcxY3VGRzBpTXBfTDFIN1FLQmxyWXVQaVptUTN5eDJnXzFSc1YwWC1ObFBON25OOUpHWmpPUjU3aWFfaHhiV2hHdFQwTnRUVkhqY0hwTG5ONUcxWE50RWtmc1dFbDh5bHJxN1E?oc=5","date":"2026-02-16","type":"deal","source":"The Motley Fool","summary":"Got $300? 2 Biotech Stocks to Buy and Hold Forever - The Motley Fool","headline":"Got $300? 2 Biotech Stocks to Buy and Hold Forever","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPb20zcjRFS0hGV0U3cFE5T1BNb0tjeHVpMnBKNTh2NU9lUF9OZkl0UW1CXzRWWWR6cHUzcHEyLVlxMDY4R0F4VFBaRmNiaHBIUV8yT0JnTmxoYWNEMUllWEF3enlreGU1MTRfRVNCQUlpdl8yZC1nbHc3SWtWdU9XVlYyNkVGRzFuWThR?oc=5","date":"2026-02-11","type":"pipeline","source":"Mugglehead Magazine","summary":"Krystal Biotech co-founder makes Forbes 250 innovators list - Mugglehead Magazine","headline":"Krystal Biotech co-founder makes Forbes 250 innovators list","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNeXd3c2VxdkoyUVZWbXkzaEZpb0N6SFV2aU5fNUhHQjBJWTRIRFluNGRoVWI5a2Y4eDdGZ1Y2WmdQU0tqeW9ZektoVi1MTlRLcGVMQng1SFc0Zmt1ZE9VUFJ5RUVfSi1FUHI1M0hlX1JIV1M4Q1RyOTlYMU92ZDVnNUt3?oc=5","date":"2026-01-19","type":"pipeline","source":"Yahoo Finance","summary":"What Does Wall Street Think About Krystal Biotech (KRYS)? - Yahoo Finance","headline":"What Does Wall Street Think About Krystal Biotech (KRYS)?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOZHlWWWlOdzAyODhjWWtPSjFDYUdWSERfNlMxemNheF8xNVFXamRVZHdvQV9DUktHeUExOG9GVHNJQ1dOZ2gtWDFRV0x6eG83VFdiOEljNzhob21RUnhYUHFtUTlmWGpPUC0zMkNUY0hhUGk1N3ZtWmdkbWRqYVp6OFlBNUJScW42dmdIRTZJME45NmVsOWpR?oc=5","date":"2026-01-15","type":"pipeline","source":"Finviz","summary":"Apellis Stock Crashes 23% in a Week: Here's What You Should Know - Finviz","headline":"Apellis Stock Crashes 23% in a Week: Here's What You Should Know","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-10","type":"earnings","source":"simplywall.st","summary":"Investors Shouldn't Be Too Comfortable With Krystal Biotech's (NASDAQ:KRYS) Earnings - simplywall.st","headline":"Investors Shouldn't Be Too Comfortable With Krystal Biotech's (NASDAQ:KRYS) Earnings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxNbUhEWU5MNmNVYllTWGEzZmQzN2otNDUtcFUwX0ZDdThhSDBEWDFmM0stX0RkV0YtSmVtZXlHVlNYUjhSdUtIY054bzFtNG96aldBQ2tfLXFLUGx3YzNKdGF6eEltWG1hLURoZWRXN1ZDOTFxN1Jzbjc5eHIxWl9DandyVDVPX2swQWFOc2VibV9rQkVtSUo4Y1ZYczdhWGM5Z3kxUUowT1pRaGNpZGZYa2plYVMzN1pWNTNibm9Xb3k3dEJrVjRLdzlLTVVfeVhBMlgwamdQU1RiZjhYOHJ6aFJ5WXZxdGRwT1g5VExB?oc=5","date":"2025-11-03","type":"earnings","source":"TradingView","summary":"Krystal Biotech Inc reports results for the quarter ended September 30 - Earnings Summary - TradingView","headline":"Krystal Biotech Inc reports results for the quarter ended September 30 - Earnings Summary","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-09","type":"earnings","source":"simplywall.st","summary":"Market Participants Recognise Krystal Biotech, Inc.'s (NASDAQ:KRYS) Earnings Pushing Shares 29% Higher - simplywall.st","headline":"Market Participants Recognise Krystal Biotech, Inc.'s (NASDAQ:KRYS) Earnings Pushing Shares 29% Higher","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxQcmZSUkE2OXdmcHhVd2E0M0hDRDlnUHhHZ2R6N3JKSUEyYmpjTWh0Y01ZQUNVcWpHdEpMRFVDQWZQa3VsWnVsVHNGSjNBLTBkZzlmSHpKMzlEbVkzNXpRREI4cUNTOUprUVRWNFFwWTE4NXllNzktcVdBV09WWDBkWXg0bURESDN2N3d0Z2JOaHBBRkNjMEhiSU9zRlJ6VTdkRGcxeWhqMEppYnAtbW13ZVcxVW5tYklFU2J6dVdsYWR1N19aMlJFZXBxLVZsUF9odlBfb0ZaUmdDdGh5UllzdDNqdVRjd2licXdEcmlFcU54UUpH?oc=5","date":"2025-09-30","type":"pipeline","source":"Sahm","summary":"6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner - Sahm","headline":"6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPYWF1OGMwRFNPTm1NQUIwLXZNazhmOUxnOWNBVVU1QmV1THQwQjVKOUZjV2dPSWJvNkhKY1YxeHNMSXo1Z2JfdjZtdU91TkVPV0RXcy1YcU92Q0ZpRUlGemFkX3FBUjlPdlBtTTNfWmZWTHZkRlNuSVVJOUdLWEQ5QzdGNlJRakRJUXFiQUpZbGh1MXlCVENpU2VGZE5xYkU?oc=5","date":"2025-05-14","type":"pipeline","source":"MarketBeat","summary":"Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore - MarketBeat","headline":"Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNX0F4eDNuWmxKSHo4M1VGRVJQX1ZURkIyVUtjX1FfYmd0YVY5NlNnNHdHcVFlTVZ2RmJHNVdNMi1aN0VuTGJRZWlsa3NEQ0tTdmh4bzAyZmVMS0tEMTBFalFmMW54UXhNWEZvS2NSbUJxcGZnVEhaeW1TV0dXYklmWFJ3?oc=5","date":"2025-05-09","type":"pipeline","source":"Yahoo Finance","summary":"Krystal Biotech, Inc. (KRYS): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance","headline":"Krystal Biotech, Inc. (KRYS): Among the Best Cancer Stocks to Invest in for Long-Term Gain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOOTFWcDVoVDdkWlN2c096eUJSQ0hoN1Q5cG5rN1dVM3VwTy0zZTAtVWo3dTBUOXY0SWdJX2JVZWRGaV90QmNmX1RoRnBBMzhLN0lYcGV5NERRRmZnWVIyY1hPZXJ3SmJPMjJTTWNvc2h1QnZhS0lKWFVaWmJqQUlIeTdPSkNwUkVuLUlyalNnSXRaOHVXOTgyaEFUeDdPWFVhSHNYMVdIUDE4SU9YTU9UaUV2dmxNUHBSc2N6VVUyUnJLQQ?oc=5","date":"2023-05-19","type":"regulatory","source":"Krystal Biotech, Inc","summary":"Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa - Krystal Biotech, Inc","headline":"Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) f","sentiment":"positive"}],"patents":[{"drugName":"KB103","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2033-06-01","territory":"US","annualRevenue":0}],"drugCount":4,"phaseCounts":{"phase_2":1,"phase_3":2,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["BIO","VRTX","SGMO"],"therapeuticFocus":["Dermatology","Gene Therapy"],"financials":{"source":"sec_edgar+yahoo","revenue":389130000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":389130000,"period":"2025-12-31"},{"value":290515000,"period":"2024-12-31"},{"value":50699000,"period":"2023-12-31"},{"value":0,"period":"2022-12-31"},{"value":0,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":58045000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":204831000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":496304000,"cashHistory":[],"totalAssets":1333794000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":295,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":267.73,"previousClose":263.99,"fiftyTwoWeekHigh":298.3,"fiftyTwoWeekLow":122.8,"fiftyTwoWeekRange":"122.8 - 298.303","fiftyDayAverage":264.85,"twoHundredDayAverage":205.85,"beta":0.54,"enterpriseValue":6898553344,"forwardPE":25.3,"priceToBook":6.41,"priceToSales":20.25,"enterpriseToRevenue":17.73,"enterpriseToEbitda":42.34,"pegRatio":0,"ebitda":162919008,"ebitdaMargin":41.9,"freeCashflow":93933376,"operatingCashflow":200864992,"totalDebt":9339000,"debtToEquity":0.8,"currentRatio":9.95,"returnOnAssets":8.4,"returnOnEquity":18.9,"analystRating":"1.2 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":9,"targetMeanPrice":314,"targetHighPrice":371,"targetLowPrice":241,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":11.5,"institutionHeldPercent":98.7,"sharesOutstanding":29435746,"floatShares":23122077,"sharesShort":2887556,"shortRatio":9.21,"shortPercentOfFloat":9.9,"epsTrailing":6.84,"epsForward":10.58,"revenuePerShare":13.44,"bookValue":41.78,"officers":[{"age":60,"name":"Mr. Krish S. Krishnan M.B.A., M.S.","title":"Founder, Chairman, President & CEO"},{"age":60,"name":"Ms. Suma M. Krishnan","title":"Founder, President of R&D and Director"},{"age":44,"name":"Ms. Kathryn A. Romano CPA","title":"Executive VP & Chief Accounting Officer"},{"age":null,"name":"Mr. John  Thomas","title":"EVP, General Counsel & Corporate Secretary"},{"age":null,"name":"Mr. John  Karakkal","title":"Vice President of North American Sales & Marketing"},{"age":null,"name":"Dr. Stephane  Paquette Ph.D.","title":"Senior Vice President of Corporate Development"},{"age":null,"name":"Mr. Josh  Suskin","title":"Senior Director & Head of US Human Resources"},{"age":null,"name":"Mr. Laurent  Goux","title":"EVP & GM of Europe"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.krystalbio.com","phone":"412 586 5830"}}